Completed PHASE1 INTERVENTIONAL 4-arm NCT06183216

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

A Randomized, Double Blinded, Positive Controlled Phase Ⅰb Clinical Trial in Participants Aged 2 Months (42-89 Days) and 2 to 5 Years to Evaluate the Safety and Immunogenicity of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Sponsor: Sinovac Research and Development Co., Ltd.

Conditions Pneumococcal Infectious Disease

Interventions PREVNAR 13 Sinovac PCV13

Updated 7 times since 2024 Last updated: Jan 26, 2026 Started: Jan 4, 2024 Primary completion: Mar 26, 2025 Completion: Mar 26, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pneumococcal Infectious Disease and is currently completed. Sinovac Research and Development Co., Ltd. leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
May 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jan 2025 — May 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jan 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinovac Research and Development Co., Ltd.

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dali, China